Chemosensitivity of a novel Akt inhibitor, MK2206, in gastric cancer cell lines

被引：0
|
作者：
Kim, Hyosong [1 ]
Kim, Tae Soo [1 ]
Kwan, Bo Ram [1 ]
Kim, Jeong Min [1 ]
Park, Chan Hee Park [1 ]
Jeung, Hei-Cheul [1 ]
Ahn, Joong-Bae [1 ]
Shin, Sang-Joon [1 ]
Chung, Hyun Cheol [1 ]
Rha, Sun Young [1 ]
机构：
[1] Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-1986
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1986
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation
    Huang, He
    Lin, Xiao-ji
    Lin, Ying
    Yao, Ron-xin
    He, Mu-qing
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 268 - 272
  • [32] The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
    Liu, Ruixin
    Liu, Dingxie
    Trink, Eliana
    Bojdani, Ermal
    Ning, Guang
    Xing, Mingzhao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : E577 - E585
  • [33] Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
    Wilson, Jacob M.
    Kunnimalaiyaan, Selvi
    Kunnimalaiyaan, Muthusamy
    Gamblin, T. Clark
    CANCER CELL INTERNATIONAL, 2015, 15
  • [34] Evaluation of Akt molecular targets in colorectal tumors after radiotherapy and MK2206 treatment.
    Fernandes, Jennifer Marx
    Camargo, Anamaria A.
    Koyama, Fernanda C.
    CLINICAL CANCER RESEARCH, 2018, 24 (01) : 46 - 47
  • [35] Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
    Simioni, C.
    Neri, L. M.
    Tabellini, G.
    Ricci, F.
    Bressanin, D.
    Chiarini, F.
    Evangelisti, C.
    Cani, A.
    Tazzari, P. L.
    Melchionda, F.
    Pagliaro, P.
    Pession, A.
    McCubrey, J. A.
    Capitani, S.
    Martelli, A. M.
    LEUKEMIA, 2012, 26 (11) : 2336 - 2342
  • [36] Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1-nanoparticles in LKB1 mutant NSCLC
    Meng, Jieru
    Lara-Guerra, Humberto
    Ji, Lin
    Roth, Jack A.
    CANCER RESEARCH, 2012, 72
  • [37] MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition
    Sun, Dingqi
    Wang, Jinhua
    Zhang, Hui
    Liu, Shuai
    Wei, Peng
    Wang, Haoran
    Xu, Zhen
    Fu, Qiang
    Zhang, Keqin
    TRANSLATIONAL ONCOLOGY, 2020, 13 (07):
  • [38] Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
    C Simioni
    L M Neri
    G Tabellini
    F Ricci
    D Bressanin
    F Chiarini
    C Evangelisti
    A Cani
    P L Tazzari
    F Melchionda
    P Pagliaro
    A Pession
    J A McCubrey
    S Capitani
    A M Martelli
    Leukemia, 2012, 26 : 2336 - 2342
  • [39] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (vol 40, pg 1545, 2018)
    Lubet, Ronald A.
    Steele, Vernon E.
    Juliana, M. M.
    Bode, Ann
    Moeinpour, Fariba
    Grubbs, Clinton J.
    ONCOLOGY REPORTS, 2019, 41 (01) : 718 - 718
  • [40] Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis
    Jacob M Wilson
    Selvi Kunnimalaiyaan
    Muthusamy Kunnimalaiyaan
    T Clark Gamblin
    Cancer Cell International, 15
12345